<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00894283</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00025492</org_study_id>
    <nct_id>NCT00894283</nct_id>
  </id_info>
  <brief_title>Comparing Enoxaparin to Fondaparinux to Prevent Venous Thromboembolism (VTE) in Bariatric Surgical Patients</brief_title>
  <official_title>A Pilot Study to Determine the Feasibility of Conducting a Randomized Clinical Trial Comparing Fondaparinux Sodium (Arixtra) Once Daily With Enoxaparin (Lovenox®) Twice Daily With Respect to Preventing VTE After Bariatric Surgery in Obese Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>GlaxoSmithKline</agency>
      <agency_class>Industry</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is designed to determine the feasibility of conducting a randomized clinical&#xD;
      trial comparing fondaparinux sodium (Arixtra) once daily with enoxaparin (Lovenox®) twice&#xD;
      daily with respect to preventing deep vein thrombosis (DVT) and pulmonary embolism (PE) after&#xD;
      bariatric surgery in obese patients.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      In order to determine the feasibility of such a trial we need to determine the necessary&#xD;
      sample size. In order to determine the necessary sample size, we need to obtain estimates of&#xD;
      the incidence of DVT and the prevalence of PE using MRV in each treatment group. Descriptive&#xD;
      statistics and 95% confidence intervals will be calculated to determine the incidence of DVT&#xD;
      and the prevalence of PE using MRV in obese patients who have received treatment to prevent&#xD;
      DVT and PE associated with bariatric surgery.&#xD;
&#xD;
      Anti-factor Xa levels will be used to help determine if treatments are reaching appropriate&#xD;
      levels.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>June 2009</start_date>
  <completion_date type="Actual">September 2013</completion_date>
  <primary_completion_date type="Actual">September 2013</primary_completion_date>
  <phase>Early Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Factorial Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To estimate the prevalence of asymptomatic deep venous thrombosis and pulmonary emboli in obese patients undergoing bariatric surgery.</measure>
    <time_frame>2 years</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the relationship of Anti-factor Xa levels and the occurrence of deep venous thrombosis and pulmonary emboli in bariatric patients receiving standard dose of anticoagulation (enoxaparin/Lovenox or fondaparinux/Arixtra).</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">198</enrollment>
  <condition>Deep Venous Thrombosis</condition>
  <condition>Pulmonary Embolism</condition>
  <arm_group>
    <arm_group_label>Enoxaparin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Fondaparinux</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Enoxaparin</intervention_name>
    <description>Patients will receive enoxaparin 40mg subcutaneously twice daily during perioperative period of bariatric surgery. Patients will be encouraged to ambulate and compression stockings while in bed.</description>
    <arm_group_label>Enoxaparin</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Fondaparinux</intervention_name>
    <description>Fondaparinux 5mg subcutaneously 6 hours following surgery, fondaparinux 5mg subcutaneously once daily during hospitalization. Patients will be encouraged to ambulate and compression stockings while in bed.</description>
    <arm_group_label>Fondaparinux</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          1. Men or women 18 years or older.&#xD;
&#xD;
          2. Body mass index (BMI) of 35kg/m2 or greater.&#xD;
&#xD;
          3. Undergoing laparoscopic bariatric surgery, i.e., laparoscopic sleeve gastrectomy,&#xD;
             laparoscopic Roux-en Y gastric bypass or laparoscopic duodenal switch.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. History of previous deep vein thrombosis.&#xD;
&#xD;
          2. History of previous pulmonary emboli.&#xD;
&#xD;
          3. History of documented clotting/coagulation disorder.&#xD;
&#xD;
          4. History of cancer.&#xD;
&#xD;
          5. Weight &lt; 50 kg or &gt; 200 kg or unable to fit in MRI scanner.&#xD;
&#xD;
          6. Presence of metallic foreign bodies&#xD;
&#xD;
          7. Recent history of smoking (within the last year).&#xD;
&#xD;
          8. History of venous stasis disease.&#xD;
&#xD;
          9. History of obesity hypoventilation syndrome.&#xD;
&#xD;
         10. Patients who are unable to lay flat for extended periods of time or are&#xD;
             claustrophobic.&#xD;
&#xD;
         11. Patients who have a pacemaker, an implanted defibrillator or certain other implanted&#xD;
             or electronic or metallic devices (implanted medical or metallic devices, shrapnel, or&#xD;
             metal).&#xD;
&#xD;
         12. History of hypersensitivity reaction to anticoagulation products.&#xD;
&#xD;
         13. History of HIT (Heparin Induced Thrombocytopenia.&#xD;
&#xD;
         14. History of Renal Insufficiency (Creatinine Clearance &lt; 50).&#xD;
&#xD;
         15. Active clinically significant bleeding.&#xD;
&#xD;
         16. Acute bacterial endocarditis.&#xD;
&#xD;
         17. BMI &gt; 60.&#xD;
&#xD;
         18. Patients with metallic foreign body or implant (unable to have an MRV study).&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>70 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Kimberley E Steele, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Johns Hopkins Bayview Medical Center</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2019</verification_date>
  <study_first_submitted>May 5, 2009</study_first_submitted>
  <study_first_submitted_qc>May 5, 2009</study_first_submitted_qc>
  <study_first_posted type="Estimate">May 6, 2009</study_first_posted>
  <last_update_submitted>June 5, 2019</last_update_submitted>
  <last_update_submitted_qc>June 5, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">June 7, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>DVT</keyword>
  <keyword>PE</keyword>
  <keyword>MRV</keyword>
  <keyword>bariatric surgery</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Pulmonary Embolism</mesh_term>
    <mesh_term>Thrombosis</mesh_term>
    <mesh_term>Embolism</mesh_term>
    <mesh_term>Venous Thrombosis</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Enoxaparin</mesh_term>
    <mesh_term>PENTA</mesh_term>
    <mesh_term>Fondaparinux</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

